SS-31 (Szeto-Schiller Peptide) Mechanism: Mitochondria-Targeted Tetrapeptide

SS-31 — also designated elamipretide in the development literature, and named for its developers Hazel Szeto and Peter Schiller — is a small synthetic tetrapeptide engineered to selectively concentrate at the inner mitochondrial membrane, where it interacts with cardiolipin and stabilizes electron transport chain (ETC) supercomplexes. Among the mitochondria-targeted research peptide class, SS-31 occupies a distinct mechanistic niche from the mitochondrial-derived peptides (MOTS-c, humanin) — it is a synthetic targeting peptide, not a peptide encoded by the mitochondrial genome.

SS-31 is supplied for in vitro and animal-research applications only. Nothing in this article should be read as a therapeutic recommendation.

Reference identifiers

CAS Registry Number: 736992-21-5
Molecular formula: C₃₂H₄₉N₉O₅
Molecular weight: ~639.8 g/mol
Sequence (4 aa): D-Arg-2′,6′-Dmt-Lys-Phe-NH₂ (Dmt = 2,6-dimethyltyrosine)
Form supplied: Lyophilized white powder

The sequence is unusual for a research peptide: only four residues, with two non-standard components (D-arginine in position 1, the 2,6-dimethyltyrosine in position 2). These structural features are essential to the mitochondrial-targeting mechanism. A CoA should confirm HPLC purity ≥99.0%, mass spec [M+H]⁺ at ~640 within ±0.5 Da, and the presence of the non-natural residues by amino acid analysis or tandem MS sequencing.

Mechanism — cardiolipin targeting

The core mechanism of SS-31 is its selective accumulation in the inner mitochondrial membrane through interaction with cardiolipin, the unique phospholipid that constitutes ~20% of the inner-membrane lipid composition. Cardiolipin’s tetra-acyl structure carries net negative charge at physiological pH, providing the electrostatic anchor for SS-31’s alternating cationic-aromatic structural motif.

The alternating-charge motif — cationic (D-Arg, Lys) and aromatic (Dmt, Phe) — is the defining “Szeto-Schiller” design principle. The cationic residues drive concentration in the mitochondrial matrix (which carries negative membrane potential ~150 mV); the aromatic residues then anchor the peptide at the cardiolipin-rich inner-membrane interface [Szeto HH, 2014, British Journal of Pharmacology, DOI 10.1111/bph.12461].

Once concentrated at the cardiolipin interface, SS-31 stabilizes:

– The structural organization of ETC supercomplexes (I+III+IV “respirasome” assembly)

– The integrity of cardiolipin against peroxidative damage under oxidative stress

– The functional coupling between ETC electron flow and ATP synthesis

– Mitochondrial cristae architecture, which depends on cardiolipin organization

In animal-study models of mitochondrial dysfunction — including aged tissues, ischemia-reperfusion, and inherited mitochondrial cardiomyopathy models — the published literature reports preserved mitochondrial respiratory capacity, reduced reactive oxygen species (ROS) production, and protected cristae structure under SS-31 treatment [Birk AV et al., 2014, JASN, DOI 10.1681/ASN.2013111118; Chiao YA et al., 2020, eLife, DOI 10.7554/eLife.55513].

Preclinical animal-study findings

The published SS-31 preclinical literature has investigated:

Aged-animal cardiac function — reported improvements in diastolic function, cardiomyocyte mitochondrial respiratory capacity, and ROS markers in aged mouse models under sustained SS-31 administration
Ischemia-reperfusion injury models — reported reductions in infarct size and preserved mitochondrial respiration in cardiac and renal ischemia-reperfusion designs
Inherited mitochondrial cardiomyopathy — preclinical work in Barth syndrome models (tafazzin deficiency) and other inherited mitochondrial disorders
Aged-skeletal muscle function — reported improvements in mitochondrial respiratory chain function and exercise capacity in aged mouse models
Neuronal models of mitochondrial dysfunction — work in Parkinson’s disease and Alzheimer’s disease cell and animal models

These are research observations. None constitute evidence of safety or efficacy in any species, including humans.

Why SS-31 is mechanistically distinctive

Compared to other research peptides in the mitochondrial-biology space:

MOTS-c (mitochondrial-derived peptide): acts as a signaling molecule, modulating AMPK and metabolic adaptation. SS-31 is a structural-stabilizer peptide, not a signaling molecule.
Humanin (mitochondrial-derived peptide): acts via cytoplasmic anti-apoptotic mechanisms. Different cellular compartment and different mechanism.
Antioxidant small molecules (CoQ10 analogs, MitoQ): also localize to mitochondria, but through different chemical strategies (lipophilic cation tethering, ubiquinone scaffold). SS-31’s peptide structure and cardiolipin-binding mode are distinct.

For broader background on mitochondrial-biology research peptides, see the MOTS-c mitochondrial peptide overview.

Pharmacokinetic notes

SS-31 has favorable pharmacokinetic properties for a research peptide: it is small (4 residues), water-soluble, and has reported parenteral bioavailability adequate for animal-model administration. Plasma half-life in animal models is reported in the multi-hour range — longer than most unmodified short peptides because the structural design that drives mitochondrial concentration also provides some protection from proteolytic degradation.

CoA verification

A research-grade SS-31 CoA should document:

– HPLC purity ≥99.0% with chromatogram

– Mass spectrum confirming ~640 Da [M+H]⁺

– D-arginine confirmation in position 1 — D vs. L stereochemistry can be verified by chiral HPLC; substitution of L-Arg in position 1 abolishes the mitochondrial-targeting mechanism

– 2,6-Dimethyltyrosine confirmation in position 2

– Net peptide content with counterion identified

– Lot number matching vial

The stereochemistry check is critical for SS-31. The defining structural feature is the alternating cationic-aromatic motif with specific stereochemistry; an L-Arg substitution in position 1 is not the same compound.

Storage

SS-31 is supplied lyophilized. Pre-reconstitution: 2–8°C dry, dark; -20°C archival storage. Post-reconstitution: 2–8°C, use within ~28 days. The small peptide is robust to standard handling protocols.

Summary

SS-31 is a synthetic mitochondria-targeted tetrapeptide that concentrates in the inner mitochondrial membrane through cardiolipin binding, stabilizing ETC supercomplexes and cardiolipin integrity. The alternating cationic-aromatic motif with specific D-Arg and 2,6-dimethyltyrosine residues is the defining structural feature. Preclinical animal-study literature reports preserved mitochondrial respiratory function and reduced ROS production across aged-tissue, ischemia-reperfusion, and inherited mitochondrial disorder models.

Research Use Only. Not for use in or on humans or animals. Not a food, drug, cosmetic, or supplement.